glucagon like peptide 1 glp 1 receptor agonist medications Glucagon-like peptide-1 20 Companies in Glucagon-Like Peptide-1

Indirect mechanisms relate to weight loss, improved glycaemic control, and reduced visceral adiposityall of which independently contribute to lower inflammatory burden

Women should not only rely on oral contraception in such a situation but either add a barrier contraception method for 4 weeks after initiation until four 4 weeks after the last dose escalation of tirzepatide or switch to a completely nonoral contraceptive method (61)

A 2025 study examined the effects of both semaglutide and tirzepatide on participants with obesity

2022-2032) Type 2 Diabetes Obesity Cardiovascular Diseases Liver Cirrhosis Non-alcoholic fatty liver disease (NAFLD) Others End-Use Outlook (Revenue, USD Billion

By Application: T2DM dominates, Obesity growing fastest Type 2 Diabetes Mellitus maintained the dominant application position in the GLP-1 Receptor Agonist Market in 2025, driven by the large established prescriber base, comprehensive insurance coverage for diabetes indications, and the longer clinical history of GLP-1 therapy in diabetes management that has built physician comfort and treatment guideline endorsement